文献速递肾小球疾病

靶向内皮素A受体治疗IgA肾病

Targeting the Endothelin A Receptor in IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2023-08-04

本文综述靶向内皮素A受体(ETAR)在IgA肾病治疗中的证据。ETAR激活可致血管收缩、细胞增殖、炎症、凋亡和纤维化;阻断ETAR在实验模型中具肾脏保护作用,在IgA肾病患者中可降低蛋白尿。综述还讨论了该类药物的潜在角色。

要点

  • ETAR激活介导血管收缩、增殖、炎症、凋亡和纤维化等病理效应。
  • 阻断ETAR在IgA肾病实验模型中具肾脏保护作用。
  • 阻断ETAR在IgA肾病患者中可降低蛋白尿。

核心结论

  • 阻断内皮素A受体在IgA肾病实验模型中具肾脏保护作用,在患者中可降低蛋白尿。

研究设计与样本

  • 综述,讨论支持ETAR阻断用于IgA肾病的证据及其在当前和新兴治疗中的潜在角色。

主要发现

  • ETAR在多种肾脏细胞类型上的激活引发血管收缩、细胞增殖、炎症、凋亡和纤维化。
  • 阻断ETAR在IgA肾病实验模型中具肾脏保护作用。
  • 阻断ETAR在IgA肾病患者中降低蛋白尿。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and carries a substantial risk of kidney failure. New agency-approved therapies, either specifically for IgAN or for chronic kidney disease (CKD) in general, hold out hope for mitigating renal deterioration in patients with IgAN. The latest addition to this therapeutic armamentarium targets the endothelin-A receptor (ETAR). Activation of ETAR on multiple renal cell types elicits a host of pathophysiological effects, including vasoconstriction, cell proliferation, inflammation, apoptosis, and fibrosis. Blockade of ETAR is renoprotective in experimental models of IgAN and reduces proteinuria in patients with IgAN. This review discusses the evidence supporting the use of ETAR blockade in IgAN as well as addressing the potential role for this class of agents among the current and emerging therapies for treating this disorder.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kohan DE, Barratt J, Heerspink HJL, et al. Targeting the Endothelin A Receptor in IgA Nephropathy. Kidney Int Rep. 2023. PMID: 38025243. doi:10.1016/j.ekir.2023.07.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。